(Q36031471)

11 August 2017

Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study (English)

1 reference

11 August 2017

lymphoblastic leukemia

1 reference

Smita Bhatia

1

1 reference

11 August 2017

Wendy Landier

2

1 reference

11 August 2017

Lindsey Hageman

3

1 reference

11 August 2017

Yanjun Chen

4

1 reference

11 August 2017

Heeyoung Kim

5

1 reference

11 August 2017

Can-Lan Sun

6

1 reference

11 August 2017

Nancy Kornegay

7

1 reference

11 August 2017

William E Evans

8

1 reference

11 August 2017

Anne L Angiolillo

9

1 reference

11 August 2017

Bruce Bostrom

10

1 reference

11 August 2017

Jacqueline Casillas

11

1 reference

11 August 2017

Glen Lew

12

1 reference

11 August 2017

Kelly W Maloney

13

1 reference

11 August 2017

Leo Mascarenhas

14

1 reference

11 August 2017

A Kim Ritchey

15

1 reference

11 August 2017

Amanda M Termuhlen

16

1 reference

11 August 2017

William L Carroll

17

1 reference

11 August 2017

F Lennie Wong

18

1 reference

11 August 2017

Mary V Relling

19

1 reference

11 August 2017

1 June 2015

1 reference

11 August 2017

1 reference

11 August 2017

1

1 reference

11 August 2017

3

1 reference

11 August 2017

287-295

1 reference

6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Chemotherapy dosing schedule influences drug resistance development in ovarian cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Cytogenetics in acute leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

6-Mercaptopurine dose escalation and its effect on drug tolerance in childhood lymphoblastic leukaemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Importance of 6-mercaptopurine dose in lymphoblastic leukaemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Relapse in acute lymphoblastic leukemia as a function of white blood cell and absolute neutrophil counts during maintenance chemotherapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

6-Mercaptopurine cumulative dose: a critical factor of maintenance therapy in average risk childhood acute lymphoblastic leukemia.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4561178

Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia

23 September 2018

1 reference

12 December 2020

Assay of 6-mercaptopurine and its metabolites in patient plasma by high-performance liquid chromatography with diode-array detection

1 reference

12 December 2020

Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia

1 reference

12 December 2020

Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia

1 reference

12 December 2020

Maintenance chemotherapy for childhood acute lymphoblastic leukemia: should dosage be guided by white blood cell counts?

1 reference

12 December 2020

Prognostic Significance of Methotrexate and 6-Mercaptopurine Dosage During Maintenance Chemotherapy for Childhood Acute Lymphoblastic Leukemia

1 reference

12 December 2020

Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology

1 reference

12 December 2020

Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine

1 reference

12 December 2020

10.1001/JAMAONCOL.2015.0245

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

26181173

1 reference